Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Ovarian Cancer|Pancreas Cancer|Prostate Cancer|BRCA1 Mutation|BRCA-Mutated Ovarian Carcinoma|BRCA-Associated Breast Carcinoma|HRD Positive Advanced Ovarian Cancer
Interventions: DRUG: TNG348|DRUG: Olaparib
Sponsor: Tango Therapeutics, Inc.